282 related articles for article (PubMed ID: 31409760)
1. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Wang J; Wei H; Huang Y; Chen D; Zeng G; Lian Y; Huang Y
Aging (Albany NY); 2019 Aug; 11(15):5769-5785. PubMed ID: 31409760
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
3. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
4. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
7. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma.
Li X; Zhou Y; Yang L; Ma Y; Peng X; Yang S; Li H; Liu J
J Cell Physiol; 2020 Apr; 235(4):3402-3413. PubMed ID: 31549407
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
Wang TT; Hong YF; Chen ZH; Wu DH; Li Y; Wu XY; Huang HQ; Zhang Q; Jia CC
Biochem Biophys Res Commun; 2021 Jun; 558():14-21. PubMed ID: 33894673
[TBL] [Abstract][Full Text] [Related]
9. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
Turcios L; Chacon E; Garcia C; Eman P; Cornea V; Jiang J; Spear B; Liu C; Watt DS; Marti F; Gedaly R
PLoS One; 2019; 14(2):e0212538. PubMed ID: 30794613
[TBL] [Abstract][Full Text] [Related]
10. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
Hong M; Almutairi MM; Li S; Li J
Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
12. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system.
Wu SY; Lan SH; Wu SR; Chiu YC; Lin XZ; Su IJ; Tsai TF; Yen CJ; Lu TH; Liang FW; Li CY; Su HJ; Su CL; Liu HS
Hepatology; 2018 Jul; 68(1):141-154. PubMed ID: 29328502
[TBL] [Abstract][Full Text] [Related]
14. Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells.
Kwon HY; Kim JH; Kim B; Srivastava SK; Kim SH
Arch Toxicol; 2018 Jan; 92(1):241-257. PubMed ID: 28676953
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
17. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
Zhao F; Feng G; Zhu J; Su Z; Guo R; Liu J; Zhang H; Zhai Y
Anticancer Drugs; 2021 Apr; 32(4):386-393. PubMed ID: 33395067
[TBL] [Abstract][Full Text] [Related]
18. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
19. Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.
Xiao MC; Qian H; Huang CK; Zheng BN; Yan FZ; Liu F; Zhang X; Chen SJ; Luo C; Xie WF
Eur J Pharmacol; 2021 Sep; 906():174217. PubMed ID: 34087223
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
